Eli Lilly & Co. expands immuno-oncology collaboration with Merck
They will add a new study of Lilly's Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).
Notably, the U.S. Food and Drug Administration (FDA) recently granted accelerated approval for Lartruvo in combination with doxorubicin, for the treatment of adults with STS with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
Lartruvo in combination with doxorubicin, also recently received conditional marketing authorization from the European Medicines Agency for the treatment of adults with advanced STS not amenable to curative treatment.
What to read next